
|Videos|August 6, 2021
Dr. Ketan K. Badani discusses the significance of PSMA agents
Author(s)Urology Times staff
“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.
Advertisement
In this video, Ketan K. Badani, MD, shares a key takeaway in prostate cancer from the 2021 ASCO annual meeting. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
3
Pearls & Perspectives: Expanding Options for Men With Erectile Dysfunction, With Tom Riester
4
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
5











